Literature DB >> 16782007

Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression.

Takuya Yamamoto1, Miki Ebisuya, Fumito Ashida, Kazuo Okamoto, Shin Yonehara, Eisuke Nishida.   

Abstract

BACKGROUND: The ERK family of MAP kinase plays a critical role in growth factor-stimulated cell-cycle progression from G0/G1 to S phase. It has been suggested that sustained activation, but not transient activation, of ERK is necessary for inducing S phase entry. Although the essential role of ERK MAP kinase in growth factor-stimulated gene expression, especially expression of immediate-early genes, is well established, it has remained unclear how ERK activity duration affects the promotion of G1 phase progression to S phase.
RESULTS: We have found that inhibition of ERK activation by the MEK inhibitor or dominant-negative MEK1 even immediately before the onset of S phase leads to the cessation of S phase entry. Our analyses reveal that there are ERK-dependent downregulated genes, whose expression levels return to their original levels rapidly after ERK inactivation, and that their downregulation mostly requires AP-1 activity. Remarkably, microinjection experiments demonstrate that many of the downregulated genes act as antiproliferative genes during G1 phase and that their forced expression to the levels before growth factor stimulation even in late G1 phase blocks S phase entry.
CONCLUSIONS: Thus, continuous ERK activation downregulates antiproliferative genes until the onset of S phase to allow successful G1 phase progression. This mechanism may also work as a fail-safe mechanism, which prevents inappropriate stimuli that induce transient ERK activation from causing S phase entry.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16782007     DOI: 10.1016/j.cub.2006.04.044

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  87 in total

Review 1.  Mitochondrial regulation of cell cycle and proliferation.

Authors:  Valeria Gabriela Antico Arciuch; María Eugenia Elguero; Juan José Poderoso; María Cecilia Carreras
Journal:  Antioxid Redox Signal       Date:  2012-01-13       Impact factor: 8.401

2.  Shoc2-tranduced ERK1/2 motility signals--Novel insights from functional genomics.

Authors:  Myoungkun Jeoung; Eun Ryoung Jang; Jinpeng Liu; Chi Wang; Eric C Rouchka; Xiaohong Li; Emilia Galperin
Journal:  Cell Signal       Date:  2016-02-11       Impact factor: 4.315

3.  MAPK1 up-regulates the expression of MALAT1 to promote the proliferation of cardiomyocytes through PI3K/AKT signaling pathway.

Authors:  Jing Zhao; Li Li; Ling Peng
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

4.  ERK activity and G1 phase progression: identifying dispensable versus essential activities and primary versus secondary targets.

Authors:  Jessie Villanueva; Yuval Yung; Janice L Walker; Richard K Assoian
Journal:  Mol Biol Cell       Date:  2007-02-21       Impact factor: 4.138

5.  MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer.

Authors:  Mick D Edmonds; Kelli L Boyd; Tamara Moyo; Ramkrishna Mitra; Robert Duszynski; Maria Pia Arrate; Xi Chen; Zhongming Zhao; Timothy S Blackwell; Thomas Andl; Christine M Eischen
Journal:  J Clin Invest       Date:  2015-12-14       Impact factor: 14.808

6.  Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways.

Authors:  Paraskevi Xekouki; Monalisa Azevedo; Constantine A Stratakis
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09-01

Review 7.  Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes.

Authors:  Scott T Eblen
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

8.  Endothelial cells isolated from caveolin-2 knockout mice display higher proliferation rate and cell cycle progression relative to their wild-type counterparts.

Authors:  Leike Xie; Philippe G Frank; Michael P Lisanti; Grzegorz Sowa
Journal:  Am J Physiol Cell Physiol       Date:  2009-12-09       Impact factor: 4.249

9.  Constitutively active RhoA inhibits proliferation by retarding G(1) to S phase cell cycle progression and impairing cytokinesis.

Authors:  Pierre Morin; Cristina Flors; Michael F Olson
Journal:  Eur J Cell Biol       Date:  2009-06-09       Impact factor: 4.492

10.  From pathway to population--a multiscale model of juxtacrine EGFR-MAPK signalling.

Authors:  D C Walker; N T Georgopoulos; J Southgate
Journal:  BMC Syst Biol       Date:  2008-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.